Zura Bio ( (ZURA) ) has issued an update.
On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.
More about Zura Bio
Zura Bio is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company is advancing a portfolio that includes tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a focus on demonstrating their efficacy, safety, and dosing convenience for conditions like systemic sclerosis.
YTD Price Performance: -40.43%
Average Trading Volume: 515,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $91.41M
For detailed information about ZURA stock, go to TipRanks’ Stock Analysis page.